|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.840 USD | +1.97% |
|
-0.61% | +26.15% |
| 06-29 | BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs | RE |
| 06-29 | BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bullish | Bullish |
| Resistance | 10 | 10 | 9.94 |
| Spread/Res. | -1.60% | -1.60% | -1.01% |
| Spread/Supp. | +7.89% | +20.15% | +18.70% |
| Support | 9.12 | 8.19 | 8.29 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- BCRX Stock
- Charts BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
